ZKGZ 002
Alternative Names: ZKGZ-002Latest Information Update: 09 Oct 2023
At a glance
- Originator Zhaoke Pharmaceutical (Guangzhou)
- Developer Lee's Pharmaceutical
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiovascular disorders
Most Recent Events
- 04 Oct 2023 Phase-II clinical trials in Cardiovascular disorders in China (unspecified route) (Lee's Pharmaceutical pipeline - October 2023)
- 10 Dec 2020 Phase-I clinical trials in Cardiovascular disorders in China (unspecified route) before December 2020 (Lee's Pharmaceutical pipeline, December 2020)